4.82
-0.35 (-6.77%)
| Previous Close | 5.17 |
| Open | 5.10 |
| Volume | 3,208,057 |
| Avg. Volume (3M) | 4,037,360 |
| Market Cap | 1,678,333,568 |
| Price / Sales | 12.70 |
| Price / Book | 5.63 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,913.23% |
| Diluted EPS (TTM) | -2.20 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 9.01 |
| Operating Cash Flow (TTM) | -157.34 M |
| Levered Free Cash Flow (TTM) | -64.76 M |
| Return on Assets (TTM) | -23.33% |
| Return on Equity (TTM) | -119.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Nuvation Bio Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 2.0 |
| Average | -0.38 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.14% |
| % Held by Institutions | 62.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 31 Mar 2026 | 25,954,439 |
| Omega Fund Management, Llc | 31 Mar 2026 | 8,081,089 |
| Laurion Capital Management Lp | 31 Mar 2026 | 7,822,638 |
| Duquesne Family Office Llc | 31 Mar 2026 | 4,539,800 |
| Redmile Group, Llc | 31 Mar 2026 | 3,153,256 |
| Tang Capital Management Llc | 31 Mar 2026 | 3,149,557 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |